SecBot SecBot
PRESS-RELEASE ·Filed Jul 8, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The NEJM publication adds credibility to setmelanotide's efficacy in acquired hypothalamic obesity, which may accelerate physician adoption. With FDA and EMA approvals already in place, the commercial focus is on market penetration. Monitor quarterly revenues for uptick in prescriptions.

DirectionBullish
Confidencehigh
Horizonweeks

IMCIVREE

▲ Bullish Named in this press release
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$115.48
T+0 close · Jul 8, 2026 · via day close
Latest settled
−19.61%
T+60 · $92.83
Vs SPY
−21.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 9 $115.48entry
  2. T+1 · 4mo ago −6.13%α −6.56% · $108.40
  3. T+5 · 4mo ago −8.13%α −8.00% · $106.09
  4. T+20 · 3mo ago −2.93%α −5.17% · $112.10
  5. T+60 · 7w ago −19.61%α −21.25% · $92.83
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE) in acquired hypothalamic obesity were published in The New England Journal of Medicine. The data show a -19.8% placebo-adjusted BMI reduction with 80% of patients achieving ≥5% BMI reduction at 52 weeks. The publication reinforces the drug's efficacy after FDA approval (March 2026) and EMA recommendation, potentially supporting commercial adoption in a rare disease with no prior approved therapy.

Key Facts

  • Placebo-adjusted BMI reduction of -19.8% (p<0.0001) in Phase 3 TRANSCEND trial
  • 80% of setmelanotide-treated patients achieved ≥5% BMI reduction at 52 weeks
  • Setmelanotide was generally well tolerated with no new safety signals
  • FDA approval for acquired hypothalamic obesity obtained in March 2026; EMA CHMP recommended approval in March 2026
  • Results published in The New England Journal of Medicine, validating prior topline data

Financial Impact

Publication in NEJM validates efficacy and may support commercial adoption; no financial data provided in the release.

revenue

Risk Factors

  • Competition from other obesity therapies (e.g., GLP-1 agonists) for broader obesity but limited for this rare indication
  • Safety signals including adrenal insufficiency, depression, and skin hyperpigmentation may limit uptake

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3324480

Track record

26 reports on RYTM

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026